Stock Alert: Enlivex Therapeutics Tanks 22%

By RTTNews Staff Writer   ✉   | Published:

Shares of Enlivex Therapeutics Ltd. (ENLV) tanked over 22% on Monday morning despite no stock-related news.

ENLV is currently trading at $8.86, down $2.64 or 22.96%, on the Nasdaq.

Enlivex Therapeutics, a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing.

Last week, the company announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent application covering methods of using Allocetra, the company's immunotherapy product candidate.

The new patent will provide added intellectual property protection for methods of treating autoimmune and inflammatory diseases comprising gout, inflammatory bowel disease, Crohn's disease, and ulcerative colitis.

The company expects that this new patent will be issued in the United States in the coming months.

For comments and feedback contact: editorial@rttnews.com

Business News

Previous Story
Next Story
Editors Pick
FDA Authorizes First Serology Test That Detects COVID-19 Neutralizing Antibodies
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for GenScript USA Inc.'s "cPass SARS-CoV-2 Neutralization Antibody Detection Kit" as the world's first serology test that detects neutralizing antibodies (NAbs) from recent or prior SARS-CoV-2 infection.
Pfizer, BioNTech: COVID-19 Vaccine Candidate More Than 90% Effective
Pharmaceutical giant Pfizer Inc. (PFE) and German biotech firm BioNTech SE (BNTX) said Monday that their coronavirus vaccine candidate, BNT162b2, was found to be more than 90 percent effective in preventing COVID-19 among patients without prior evidence of infection. The results were based on the first interim efficacy analysis conducted from the vaccine's Phase 3 clinical study.
McDonald's Q3 Profit Rises, Tops View
McDonald's Corp. (MCD) reported a profit for the third-quarter that increased about 10 percent from last year, reflecting stronger operating performance in the U.S. due to higher sales-driven restaurant margins, partly offset by sales performance declines in the International Operated Markets and International Developmental Licensed Markets segments as a result of COVID-19.